Barry Hafkin

2.5k total citations
35 papers, 2.0k citations indexed

About

Barry Hafkin is a scholar working on Infectious Diseases, Pharmacology and Molecular Biology. According to data from OpenAlex, Barry Hafkin has authored 35 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 8 papers in Pharmacology and 7 papers in Molecular Biology. Recurrent topics in Barry Hafkin's work include Antimicrobial Resistance in Staphylococcus (20 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Antibiotic Resistance in Bacteria (5 papers). Barry Hafkin is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (20 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Antibiotic Resistance in Bacteria (5 papers). Barry Hafkin collaborates with scholars based in United States, Canada and Argentina. Barry Hafkin's co-authors include Dennis L. Stevens, Vu Le, Nachum Kaplan, Donald H. Batts, John L. Hunt, Harry Lampiris, Daniel Herr, David J. Kuter, Félix Arellano and Stanton L. Gerson and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Neurology and Clinical Infectious Diseases.

In The Last Decade

Barry Hafkin

35 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barry Hafkin United States	20	1.4k	631	416	410	356	35	2.0k
Jeff Alder United States	24	1.5k 1.1×	816 1.3×	771 1.9×	521 1.3×	838 2.4×	37	3.0k
Donald H. Batts United States	17	1.3k 0.9×	539 0.9×	500 1.2×	351 0.9×	181 0.5×	22	1.7k
S. J. van Hal Australia	18	1.7k 1.3×	1.0k 1.6×	655 1.6×	553 1.3×	438 1.2×	20	2.4k
William O’Riordan United States	20	1.1k 0.8×	627 1.0×	493 1.2×	431 1.1×	190 0.5×	38	1.8k
Katie E. Barber United States	21	827 0.6×	421 0.7×	471 1.1×	405 1.0×	252 0.7×	89	1.5k
Wendy Munckhof Australia	20	1.0k 0.8×	635 1.0×	491 1.2×	395 1.0×	300 0.8×	42	1.7k
John Mohr United States	21	721 0.5×	369 0.6×	472 1.1×	378 0.9×	234 0.7×	49	1.5k
Brian J. Werth United States	25	815 0.6×	488 0.8×	320 0.8×	318 0.8×	294 0.8×	49	1.4k
Roger L. White United States	22	546 0.4×	384 0.6×	416 1.0×	620 1.5×	378 1.1×	52	2.1k
Pamela Moise United States	19	1.2k 0.9×	749 1.2×	522 1.3×	440 1.1×	286 0.8×	38	1.6k

Countries citing papers authored by Barry Hafkin

Since Specialization

Citations

This map shows the geographic impact of Barry Hafkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Hafkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Hafkin more than expected).

Fields of papers citing papers by Barry Hafkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry Hafkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Hafkin. The network helps show where Barry Hafkin may publish in the future.

Co-authorship network of co-authors of Barry Hafkin

This figure shows the co-authorship network connecting the top 25 collaborators of Barry Hafkin. A scholar is included among the top collaborators of Barry Hafkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Hafkin. Barry Hafkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bulitta, Jürgen B., Edward Fang, Martín E. Stryjewski, et al.. (2024). Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens. Antimicrobial Agents and Chemotherapy. 68(4). e0140023–e0140023. 3 indexed citations

Almeida, Deepak V., et al.. (2023). Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 67(12). e0078923–e0078923. 7 indexed citations

Eckburg, Paul B., Yigong Ge, & Barry Hafkin. (2017). Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 61(4). 43 indexed citations

Hunt, Thomas L., Nachum Kaplan, & Barry Hafkin. (2015). Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects. Journal of Chemotherapy. 28(3). 164–171. 9 indexed citations

Hafkin, Barry, Nachum Kaplan, & Thomas L. Hunt. (2015). Safety, Tolerability and Pharmacokinetics of AFN–1252 Administered as Immediate Release Tablets in Healthy Subjects. Future Microbiology. 10(11). 1805–1813. 13 indexed citations

Hafkin, Barry, Nachum Kaplan, & Brian S. Murphy. (2015). Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities. Antimicrobial Agents and Chemotherapy. 60(3). 1695–1701. 41 indexed citations

Banevicius, Mary Anné, Nachum Kaplan, Barry Hafkin, & David P. Nicolau. (2013). Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. Journal of Chemotherapy. 25(1). 26–31. 37 indexed citations

Kaplan, Nachum, Colin Garner, & Barry Hafkin. (2013). AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. European Journal of Pharmaceutical Sciences. 50(3-4). 440–446. 27 indexed citations

Kaplan, Nachum, Donald E. Awrey, Judd Berman, et al.. (2013). In vitroactivity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. Journal of Chemotherapy. 25(1). 18–25. 29 indexed citations

10.

Kaplan, Nachum, Monique Albert, Donald E. Awrey, et al.. (2012). Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor. Antimicrobial Agents and Chemotherapy. 56(11). 5865–5874. 92 indexed citations

11.

Karlowsky, James A., Nachum Kaplan, Barry Hafkin, Daryl J. Hoban, & George G. Zhanel. (2009). AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity. Antimicrobial Agents and Chemotherapy. 53(8). 3544–3548. 66 indexed citations

12.

Gerson, Stanton L., Sheldon L. Kaplan, Jon Bruss, et al.. (2002). Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy. 46(8). 2723–2726. 332 indexed citations

13.

Stevens, Dennis L., Daniel Herr, Harry Lampiris, et al.. (2002). Linezolid versus Vancomycin for the Treatment of Methicillin‐Resistant Staphylococcus aureus Infections. Clinical Infectious Diseases. 34(11). 1481–1490. 409 indexed citations

14.

Li, Zhiming, Richard J. Willke, Lionel Pinto, et al.. (2001). Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(3). 263–274. 114 indexed citations

15.

Hafkin, Barry, et al.. (1997). Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrobial Agents and Chemotherapy. 41(10). 2196–2200. 56 indexed citations

16.

Schwartz, Jules I., Wesley Tanaka, David L. Ebel, et al.. (1997). MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen¹. The Journal of Clinical Endocrinology & Metabolism. 82(5). 1373–1377. 30 indexed citations

17.

Schwartz, Jules I., Wesley Tanaka, David L. Ebel, et al.. (1997). MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen. Obstetrical & Gynecological Survey. 52(9). 555–557. 9 indexed citations

18.

Robbins, Bruce A., et al.. (1996). Safe coadministration of terbinafine and terfenadine: A placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clinical Pharmacology & Therapeutics. 59(3). 275–283. 17 indexed citations

19.

Hejkal, Thomas W., Bruce H. Keswick, Charles P. Gerba, et al.. (1982). Viruses in a community water supply associated with an outbreak of gastroenteritis and infectious hepatitis. American Water Works Association. 74(6). 318–321. 77 indexed citations

20.

Hafkin, Barry, Jonathan E. Kaplan, Christie Reed, et al.. (1982). Reintroduction of Dengue Fever into the Continental United States. American Journal of Tropical Medicine and Hygiene. 31(6). 1222–1228. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact